Status:
COMPLETED
A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Measles
Eligibility:
All Genders
12-18 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human ...
Detailed Description
The duration of treatment is 6 weeks.
Eligibility Criteria
Inclusion
- Healthy children 12 to 18 months of age.
Exclusion
- Previous receipt of measles, mumps, rubella and/or varicella vaccine.
- Prior infection or exposure to (within last 4 weeks) measles, mumps, rubella, varicella and/or zoster.
- Any medical condition that might interfere with the immune response to the given vaccines (including HIV infection and/or cancer) or has undergone immunosuppressive (weakens your body's ability to fight infection) therapy.
- History of seizures (convulsions)
- Allergies to any component of the vaccine, including sorbitol, gelatin, or neomycin.
- A recent (within the last 3 days) illness resulting in a fever (underarm temperature greater than 99.5° F \[37.5° C\]).
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT00109278
Start Date
October 1 2004
End Date
May 1 2005
Last Update
March 15 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.